Thinking of joining a study?

Register your interest

NCT04308304 | COMPLETED | Alzheimer's Disease

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

Merck Sharp & Dohme LLC

Brief Summary:

The study will investigate the effects on safety and pharmacokinetics (PK) of MK-1942 and donepezil when co-administered to participants with Alzheimer's Disease with mild-to-moderate cognitive impairment stably treated with donepezil. The objectives of this study include determining if the combination of MK-1942 with donepezil increases the incidence or severity of adverse events (AEs) previously reported for these agents, or results in unanticipated AEs in the patient population targeted for MK-1942 treatment. In addition, any changes in the PK parameters of either MK-1942 or donepezil as a result of co-administration will be assessed.

Condition or disease

Alzheimer's Disease







Estimated Enrollment : 27 participants
Masking : DOUBLE
Primary Purpose : TREATMENT
Official Title : A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Pharmacokinetics of MK-1942 Administered to Alzheimer's Disease Patients Receiving Donepezil Treatment.
Actual Study Start Date : 2021-02-16
Estimated Primary Completion Date : 2022-05-18
Estimated Study Completion Date : 2022-05-18

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 50 Years to 85 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Inclusion Criteria
  • * Body mass index (BMI) ≥18 and ≤35 kg/m\^2, inclusive.
  • * Is in good health based on medical history, physical examination, vital sign measures and electrocardiogram performed prior to randomization.
  • * Have a negative urine drug screen prior to randomization.
  • * Have a history of cognitive and functional decline with gradual onset and slow progression for at least one year before screening that is either corroborated or well-documented.
  • * Be receiving donepezil (maximum dose: ≥10-mg, ≤15-mg) for symptomatic treatment of cognitive impairment associated with Alzheimer's dementia. The dose level must be stable for at least 1 month prior to screening.
  • * Have a reliable and competent trial partner/caregiver who has a close relationship with the subject, has face-to-face contact at least three days a week for a minimum of six waking hours a week, and is willing to accompany the participant, if desired, to trial visits. The trial partner/caregiver should understand the nature of the trial and adhere to trial requirements (e.g., dosing, visit schedules, and nature and number of evaluations).
  • * Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • * Male participants must refrain from donating sperm PLUS agree to study guidelines regarding abstinent and/or contraception during the intervention period and for at least an additional 90 days (a spermatogenesis cycle) after the last dose of study intervention:
  • * A female participant is eligible to participate if she is a women of nonchildbearing potential by study criteria.
Exclusion Criteria
  • * Is positive for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus (HIV).
  • * Is at imminent risk of self-harm, based on clinical interview and responses on the Columbia-Suicide Severity Rating Scale (CSSRS), or of harm to others in the opinion of the investigator.
  • * Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pretrial (screening) visit.
  • * Has a history of uncontrolled, clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • * Candidates should not have a history of asthma, chronic obstructive pulmonary disease, urinary obstructions or gastrointestinal bleeding.
  • * Has a history of cancer (malignancy) exceptions for (1) Adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or; (2) Other malignancies which have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study.
  • * Has a history of significant multiple and/or severe allergies (e.g., food, drug, latex allergy), or has had an anaphylactic reaction or significant intolerability (i.e., systemic allergic reaction) to prescription or non-prescription drugs or food.
  • * Has evidence of a clinically relevant or unstable psychiatric disorder, based on The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria, including schizophrenia or other psychotic disorder, bipolar disorder, or delirium at the time of the pre-study (screening) visit, or has a history of clinically significant psychiatric disorder of the last 5 years.
  • * Has participated in another investigational study within 4 weeks (or 5 half-lives, whichever is greater) prior to the pre-study (screening) visit.

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

Location Details


Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.


Not yet recruiting

United States, Arkansas

Woodland Research Northwest, LLC ( Site 0004)

Rogers, arkansas, United States, 72758-6442

Not yet recruiting

United States, Florida

Velocity Clinical Research, Hallandale Beach ( Site 0002)

Hallandale Beach, florida, United States, 33009

Not yet recruiting

United States, Georgia

iResearch Atlanta ( Site 0005)

Decatur, Georgia, United States, 30030

Not yet recruiting

United States, Utah

ICON ( Site 0003)

Salt Lake City, Utah, United States, 84124